IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

BMS Breaks Ground on Bio-Plant

1:46 PM MDT | May 16, 2007 | Chemical Week Editorial Staff

Bristol-Myers Squibb (BMS) says it has begun building a biologic drug manufacturing facility at Devens, MA. The facility is expected to cost about $750 million and is scheduled to start production in 2011, following regulatory approval in 2010. Final investment in the facility will total $1.1 billion, it says. The facility will feature six 20,000-liter cell culture reactor vessels and one purification line. It is being built primarily to manufacture BMS’s rheumatoid arthritis drug Orencia, which generated sales of $89 million in...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa